Assignee
SHIRE HUMAN GENETIC THERAPIES
US·77 granted patents·69 pending applications·516 citations·filing 1995–2025
Top patents by PatentIndex Score
146 records- 0198US9308281B2MRNA therapy for Fabry diseaseSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Apr 12, 2016·40 cites·8 claims
- 0298US9061021B2mRNA for use in treatment of human genetic diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Jun 23, 2015·43 cites·14 claims
- 0397US9629804B2Lipid formulations for delivery of messenger RNASHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Apr 25, 2017·60 cites·18 claims
- 0497US9522176B2MRNA therapy for phenylketonuriaSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Dec 20, 2016·38 cites·12 claims
- 0597US9181321B2CFTR mRNA compositions and related methods and usesSHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Nov 10, 2015·50 cites·18 claims
- 0696US9713626B2CFTR mRNA compositions and related methods and usesSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Jul 25, 2017·23 cites·19 claims
- 0796US9597413B2Pulmonary delivery of mRNASHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted Mar 21, 2017·17 cites·6 claims
- 0895US11033459B2Modular vial adapterSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Jun 15, 2021·22 cites·16 claims
- 0993US9546128B2Ionizable cationic lipidsSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Jan 17, 2017·12 cites·33 claims
- 1092US10730874B2Inhibitors of plasma kallikrein and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Aug 4, 2020·7 cites·18 claims
- 1192US9220677B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Dec 29, 2015·16 cites·27 claims
- 1292US7833742B2Treatment of α-galactosidase A deficiencySHIRE HUMAN GENETIC THERAPIES·Filed 2006·Granted Nov 16, 2010·21 cites·26 claims
- 1391US11530393B2Compositions comprising iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2020·Granted Dec 20, 2022·2 cites·19 claims
- 1491US11065308B2Methods and compositions for CNS delivery of heparan n-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted Jul 20, 2021·6 cites·5 claims
- 1591US10556015B2Lysosomal targeting of enzymes, and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Feb 11, 2020·7 cites·5 claims
- 1691US10456454B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Oct 29, 2019·6 cites·27 claims
- 1791US9206235B2Peptide linkers for polypeptide compositions and methods for using sameSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Dec 8, 2015·8 cites·22 claims
- 1891US9150841B2Cells for producing recombinant iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Oct 6, 2015·8 cites·22 claims
- 1991US7833766B2Stabilized compositions of proteins having a free thiol moietySHIRE HUMAN GENETIC THERAPIES·Filed 2007·Granted Nov 16, 2010·13 cites·38 claims
- 2090US10660944B2Stable formulations for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2018·Granted May 26, 2020·5 cites·23 claims
- 2189US11471516B2CNS delivery of therapeutic agentsSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Oct 18, 2022·1 cites·17 claims
- 2289US11229661B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Jan 25, 2022·2 cites·17 claims
- 2389US9814764B2Treatment of sanfilippo syndrome type b by intrathecal administration of alpha-n-acetylglucosaminidaseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Nov 14, 2017·9 cites·20 claims
- 2489US9051556B2Purification of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Jun 9, 2015·13 cites·17 claims
- 2587US10245229B2Pulmonary delivery of mRNA to non-lung target cellsSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Apr 2, 2019·8 cites·18 claims
- 2687US2025282808A1Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseSHIRE HUMAN GENETIC THERAPIES·Filed 2024·Application pending·0 cites
- 2786US11260112B2Methods and compositions for CNS delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Mar 1, 2022·2 cites·17 claims
- 2886US10722559B2Mannose-6-phosphate bearing peptides fused to lysosomal enzymesSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Jul 28, 2020·5 cites·11 claims
- 2985US9932568B2Peptide linkers for polypeptide compositions and methods for using sameSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Apr 3, 2018·2 cites·26 claims
- 3085US7138262B1High mannose proteins and methods of making high mannose proteinsSHIRE HUMAN GENETIC THERAPIES·Filed 2000·Granted Nov 21, 2006·32 cites·63 claims
- 3185US2025281482A1Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2025·Application pending·0 cites
- 3284US9492511B2Methods and compositions for treatment of hunter syndromeSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Nov 15, 2016·4 cites·20 claims
- 3383US11065307B2Therapeutic fusion protein comprising an alpha-n-acetylglucosaminidase and a lysosomal targeting moietySHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Jul 20, 2021·2 cites·8 claims
- 3483US9523113B2Treatment of α-galactosidase A deficiencySHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Dec 20, 2016·3 cites·17 claims
- 3582US12350267B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Granted Jul 8, 2025·0 cites·20 claims
- 3682US12145959B2Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver diseaseSHIRE HUMAN GENETIC THERAPIES·Filed 2022·Granted Nov 19, 2024·0 cites·21 claims
- 3782US9932377B2Mitochondrial targeting and therapeutic use thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Apr 3, 2018·2 cites·4 claims
- 3880US10603364B2Lysosomal targeting and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2015·Granted Mar 31, 2020·2 cites·7 claims
- 3980US10344270B2Methods and compositions for treatment of Hunter syndromeSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Jul 9, 2019·2 cites·20 claims
- 4080US9682129B2Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2012·Granted Jun 20, 2017·5 cites·29 claims
- 4179US11376251B2Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2021·Granted Jul 5, 2022·0 cites·19 claims
- 4279US9957324B2Anti-FLT-1 antibodies in treating duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2014·Granted May 1, 2018·5 cites·7 claims
- 4378US12435146B2Anti-Flt-1 antibodies for treating Duchenne muscular dystrophySHIRE HUMAN GENETIC THERAPIES·Filed 2023·Granted Oct 7, 2025·0 cites·9 claims
- 4476US10695395B2Collagen 7 compositions and methods of using the sameSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Jun 30, 2020·1 cites·18 claims
- 4574US7410799B2In vivo production and delivery of erythropoietin or insulinotropin for gene therapySHIRE HUMAN GENETIC THERAPIES·Filed 2004·Granted Aug 12, 2008·1 cites·13 claims
- 4673US10711065B2Anti-FLT-1 antibodies in treating bronchopulmonary dysplasiaSHIRE HUMAN GENETIC THERAPIES·Filed 2016·Granted Jul 14, 2020·1 cites·16 claims
- 4773US10646554B2Methods and compositions for CNS delivery of arylsulfatase ASHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted May 12, 2020·0 cites·19 claims
- 4872US10568941B2Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2017·Granted Feb 25, 2020·1 cites·10 claims
- 4970US9603908B2Subcutaneous administration of iduronate-2-sulfataseSHIRE HUMAN GENETIC THERAPIES·Filed 2013·Granted Mar 28, 2017·2 cites·24 claims
- 5070US2022088132A1Methods and compositions for treating chronic lung diseasesSHIRE HUMAN GENETIC THERAPIES·Filed 2021·Application pending·0 cites
Showing the top 50 of 146 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SHIRE HUMAN GENETIC THERAPIES files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →